250 related articles for article (PubMed ID: 32540859)
1. Stromal LAG-3
Zeng H; Zhou Q; Wang Z; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Xu L; Dai B; Guo J; Liu L; Zhu Y; Xu J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540859
[TBL] [Abstract][Full Text] [Related]
2. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
3. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral TIGIT
Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
[TBL] [Abstract][Full Text] [Related]
6. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5
Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W
Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328
[TBL] [Abstract][Full Text] [Related]
7. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.
Xu Y; Zeng H; Jin K; Liu Z; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338085
[TBL] [Abstract][Full Text] [Related]
8. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.
Ye R; Zeng H; Liu Z; Jin K; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Wang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Feb; 71(2):301-310. PubMed ID: 34152439
[TBL] [Abstract][Full Text] [Related]
9. Poor clinical outcomes and immunoevasive contexture in SIRPĪ±
Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
[TBL] [Abstract][Full Text] [Related]
10. Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer.
Zhou Q; Zhang H; Wang Z; Zeng H; Liu Z; Huang Q; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Dai B; Guo J; Zhu Y; Xu L; Xu J
Int J Cancer; 2020 Dec; 147(12):3539-3549. PubMed ID: 32734613
[TBL] [Abstract][Full Text] [Related]
11. Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer.
Sun M; Zeng H; Jin K; Liu Z; Hu B; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Jun; 71(6):1497-1506. PubMed ID: 34716763
[TBL] [Abstract][Full Text] [Related]
12. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625
[TBL] [Abstract][Full Text] [Related]
13. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
14. Impact of intratumoural CD73 expression on prognosis and therapeutic response in patients with gastric cancer.
He X; Gu Y; Cao Y; Hu B; Fang H; Fei Y; Lv K; Liu X; Wang J; Lin C; Liu H; Zhang H; Li H; Li R; He H; Xu J
Eur J Cancer; 2021 Nov; 157():114-123. PubMed ID: 34508993
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response.
Qi Y; Chang Y; Wang Z; Chen L; Kong Y; Zhang P; Liu Z; Zhou Q; Chen Y; Wang J; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Y; Xu J; Zhang W
Cancer Immunol Immunother; 2019 Dec; 68(12):2067-2080. PubMed ID: 31720813
[TBL] [Abstract][Full Text] [Related]
16. Immune inactivation by neuropilin-1 predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Yu Y; Zeng H; Jin K; You R; Liu Z; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Cancer Immunol Immunother; 2022 Sep; 71(9):2117-2126. PubMed ID: 35041031
[TBL] [Abstract][Full Text] [Related]
17. Integrating molecular subtype and CD8
Li B; Jin K; Liu Z; Su X; Xu Z; Liu G; Xu J; Liu H; Chang Y; Wang Y; Zhu Y; Wang Z; Xu L; Zhang W
Cancer Immunol Immunother; 2024 Mar; 73(4):66. PubMed ID: 38430246
[TBL] [Abstract][Full Text] [Related]
18. B7-H4 correlates with clinical outcome and immunotherapeutic benefit in muscle-invasive bladder cancer.
Liu Z; Jin K; Zeng H; Shao F; Chang Y; Wang Y; Xu L; Wang Z; Cui X; Zhu Y; Xu J
Eur J Cancer; 2022 Aug; 171():133-142. PubMed ID: 35717821
[TBL] [Abstract][Full Text] [Related]
19. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
20. Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer.
Fu H; Zhu Y; Wang Y; Liu Z; Zhang J; Xie H; Fu Q; Dai B; Ye D; Xu J
Clin Cancer Res; 2018 Jul; 24(13):3069-3078. PubMed ID: 29514839
[No Abstract] [Full Text] [Related]
[Next] [New Search]
